» Articles » PMID: 12967765

Lithium and GSK-3: One Inhibitor, Two Inhibitory Actions, Multiple Outcomes

Overview
Specialty Pharmacology
Date 2003 Sep 12
PMID 12967765
Citations 201
Authors
Affiliations
Soon will be listed here.
Abstract

The intrigue of lithium, the simplest drug in the modern pharmacopoeia, extends from its complex actions in cells to its therapeutic effects as a mood stabilizer. New surprises from studies of glycogen synthase kinase 3 (GSK-3) show that lithium reduces GSK-3 activity in two ways, both directly and by increasing the inhibitory phosphorylation of GSK-3. These dual effects can act in concert to magnify the influence of lithium on crucial GSK-3-regulated functions (gene expression, cell structure and survival).

Citing Articles

GSK3 inhibition improves skeletal muscle function and whole-body metabolism in male mouse models of Duchenne muscular dystrophy.

Marcella B, Hockey B, Braun J, Whitley K, Geromella M, Baranowski R Nat Commun. 2024; 15(1):10210.

PMID: 39587049 PMC: 11589163. DOI: 10.1038/s41467-024-53886-y.


Promising tools into oxidative stress: A review of non-rodent model organisms.

Zhang Y, Li Y, Ren T, Duan J, Xiao P Redox Biol. 2024; 77:103402.

PMID: 39437623 PMC: 11532775. DOI: 10.1016/j.redox.2024.103402.


Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity.

Ahn M J Vet Sci. 2024; 25(5):e69.

PMID: 39363657 PMC: 11450387. DOI: 10.4142/jvs.24212.


Akt-activated GSK3β inhibitory peptide effectively blocks tau hyperphosphorylation.

Lee E, Lee Y, Yang S, Gong E, Kim J, Ha N Arch Pharm Res. 2024; 47(10-11):812-828.

PMID: 39325351 DOI: 10.1007/s12272-024-01513-1.


Unraveling Cancer's Wnt Signaling: Dynamic Control through Protein Kinase Regulation.

Tumen D, Heumann P, Huber J, Hahn N, Macek C, Ernst M Cancers (Basel). 2024; 16(15).

PMID: 39123414 PMC: 11312265. DOI: 10.3390/cancers16152686.